Additionally, we elucidated the specific mechanism by which SGLT2 inhibitors reduce the nuclear translocation of NF-κB and inhibit the expression of inflammatory cytokines, thereby establishing a direct link between SGLT2 inhibition and hypothalamic inflammation in metabolic diseases. This evidence concerns the gene SLC5A2 and Other metabolic disease.